title: Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.
abstract: Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse. In this registry-based retrospective study, we evaluated potential risks and benefits of thiotepa-based preparative regimens compared with BEAM (carmustine, etoposide, cytarabine, melphalan) in auto-SCT for diffuse large B-cell lymphoma (DLBCL, excluding PCNSL), follicular lymphoma (FL) or Hodgkin lymphoma (HL). A total of 14 544 patients (589 thiotepa and 13 955 BEAM) met the eligibility criteria, and 535 thiotepa- and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. No significant differences between thiotepa and BEAM groups for any survival end point were identified in the whole sample or disease entity subsets. For a more detailed analysis, 47 TEAM (thiotepa, etoposide, cytarabine, melphalan)-treated patients were compared with 75 matched BEAM patients with additional collection of toxicity data. Again, there were no significant differences between the two groups for any survival end point. In addition, the frequency of common infectious and non-infectious complications including secondary malignancies was comparable between TEAM and BEAM. These results indicate that thiotepa-based high-dose therapy might be a valuable alternative to BEAM in DLBCL, HL and FL. Further evaluation by prospective clinical trials is warranted.
authors.affiliation: Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: L
authors.initials: L
authors.lastname: Sellner
authors.affiliation: Lymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Boumendil
authors.affiliation: Lymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France.
authors.forename: H
authors.initials: H
authors.lastname: Finel
authors.affiliation: Department of Hematology, Pitié-Salpêtrière Hospital, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Choquet
authors.affiliation: University of Napoli, Napoli, Italy.
authors.forename: G
authors.initials: G
authors.lastname: de Rosa
authors.affiliation: University of Perugia, Perugia, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Falzetti
authors.affiliation: Department of Hematology, Azienda Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Scime
authors.affiliation: University Hospital Düsseldorf, Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Kobbe
authors.affiliation: Cardarelli Hospital, Napoli, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Ferrara
authors.affiliation: Service d'Hématologie Clinique, Hôpital Robert Debré, Centre Hospitalier Universitaire (CHU) de Reims, Reims, France.
authors.forename: A
authors.initials: A
authors.lastname: Delmer
authors.affiliation: Department of Hematology and Oncology, Helios Hospital Erfurt, Erfurt, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Sayer
authors.affiliation: APHP, Hopital Saint-louis, Hemato-Oncology Paris Diderot University, Sorbonne Paris Cité, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Amorim
authors.affiliation: Hematology Department, Paoli Calmettes Institute, Marseille Aix-Marseille University, Marseille, France.
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallah
authors.affiliation: Department of Hematology, Freiburg University Medical Center, Freiburg, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Finke
authors.affiliation: Hematologie, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre Bénite, France.
authors.forename: G
authors.initials: G
authors.lastname: Salles
authors.affiliation: LIRIC-U995, Hematology Department and Hematopoietic Stem Cell Transplantation Unit, University-Hospital of Lille, Lille, France.
authors.forename: I
authors.initials: I
authors.lastname: Yakoub-Agha
authors.affiliation: Department of Hemato-Oncology, Faculty Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
authors.forename: E
authors.initials: E
authors.lastname: Faber
authors.affiliation: Hematology Department, Centre Leon Berard, Lyon, France.
authors.forename: E
authors.initials: E
authors.lastname: Nicolas-Virelizier
authors.affiliation: Hematology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Facchini
authors.affiliation: Hematology Unit, Ospedale Civile, Piacenza, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Vallisa
authors.affiliation: Hematology Unit, S Maria delle Croci Hospital, Ravenna, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Zuffa
authors.affiliation: Lymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France.|Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Sureda
authors.affiliation: Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.|Lymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Dreger
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D064592:Autografts; D002330:Carmustine / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D011034:Podophyllotoxin / Q000008:administration & dosage; D012042:Registries; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D015996:Survival Rate; D013852:Thiotepa / Q000008:administration & dosage*
chemical_list: D003561:Cytarabine; D013852:Thiotepa; D011034:Podophyllotoxin; D008558:Melphalan; D002330:Carmustine